- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06468709
A Trial on the Remission Rates of Type I Autoimmune Pancreatits With High-risk of Recurrence (AIP;MMF)
A Multicenter, Prospective, Randomized Controlled Trial on the Remission Rate of Type I AIP With High-risk of Recurrence Patients Receiving Glucocorticoid Maintenance Therapy/Glucocorticoid Combined With Mycophenolate Mofetil Maintenance Therapy
Autoimmune pancreatitis (AIP) is an autoimmune disease with low incidence rate and involving the pancreas. In China, type I AIP is predominant. Glucocorticoids (GC) have a significant therapeutic effect. Even though a consensus has been reached on the effective initial GC treatment dose, type I AIP is prone to recurrence after GC induction and maintenance therapy. Currently, there is no consensus on how to reduce the disease recurrence rate in high-risk type I AIP patients. Multiple studies have shown that immunosuppressants (IM) combined with GC can effectively reduce the disease recurrence rate in IgG4 RD patients, including azathioprine, mycophenolate mofetil (MMF), etc. Among them, the incidence of adverse reactions in MMF is relatively low. As a special type of IgG4-RD, there is currently no prospective study evaluating the efficacy and safety of GC combined with MMF treatment in high-risk recurrent type I AIP patients. The smooth implementation of this project can provide new treatment ideas and evidence-based medicine for reducing the recurrence rate of high-risk type I AIP.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Autoimmune pancreatitis (AIP) is an autoimmune disease with low incidence rate and involving the pancreas. It can be divided into type I AIP and type II AIP. In China, type I AIP is predominant, accompanied by elevated IgG4 levels, diffuse or segmental pancreatic enlargement, and irregular narrowing of the pancreatic duct. Glucocorticoids (GC) have a significant therapeutic effect. Even though a consensus has been reached on the effective initial GC treatment dose, type I AIP is prone to recurrence after GC induction and maintenance therapy. Currently, there is no consensus on how to reduce the disease recurrence rate in high-risk type I AIP patients. The International Pancreatic Society has released an international consensus on AIP, indicating that the risk factors for AIP recurrence are still unclear. The following are possible signs of recurrence: IgG4>4 times the upper limit of normal value before treatment; The serum IgG4 level remained high after GC treatment; Pancreatic diffuse enlargement; IgG4-SC with proximal bile duct involvement; Involvement of extrapancreatic organs.Multiple studies have shown that immunosuppressants (IM) combined with GC can effectively reduce the disease recurrence rate in IgG4 RD patients, including azathioprine, mycophenolate mofetil (MMF), etc. Among them, the incidence of adverse reactions in MMF is relatively low. As a special type of IgG4-RD, there is currently no prospective study evaluating the efficacy and safety of GC combined with MMF treatment in high-risk recurrent type I AIP patients. The smooth implementation of this project can provide new treatment ideas and evidence-based medicine for reducing the recurrence rate of high-risk type I AIP.Main research objective: To evaluate the impact of corticosteroid monotherapy and corticosteroid combined with MMF maintenance therapy on disease remission rate in high-risk type I AIP patients with recurrence within 3 years Secondary research objective: (I) To evaluate the impact on endocrine function; (II) Evaluate the impact on external secretion function; (III) Evaluate the impact on the incidence of malignant tumors; (IV) Adverse reactions; (V) Treatment costs.
Participants will be followed for a total of 36 months. An initial analysis of 12-month follow-up data is planned, with findings intended for dissemination through scientific presentations and/or publication as preliminary results. Follow-up will continue through Month 36, after which the final analysis and dissemination of results are planned.
Peripheral blood samples will be collected during the study for exploratory mechanistic analyses of immune-cell populations and circulating biomarkers. These analyses will characterize biological changes during treatment and explore their associations with disease remission, relapse, and treatment response.
Type d'étude
Inscription (Estimé)
Phase
- Phase 4
Contacts et emplacements
Coordonnées de l'étude
- Nom: XIaonan Shen, Doctor
- Numéro de téléphone: 18817554263
- E-mail: hgssldsxn@163.com
Lieux d'étude
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Chine, 200025
- Recrutement
- Ruijin Hospital
-
Contact:
- Shen, Doctor
- Numéro de téléphone: 18817554263
- E-mail: hgssldsxn@163.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Signed informed consent form with date;
- Promise to comply with research procedures and cooperate with the implementation of the entire process research;
- Age 18 and above, regardless of gender;
- Confirmed as type I AIP and high-risk for recurrence, including the following characteristics: IgG4>4 times the upper limit of normal value before treatment; The serum IgG4 level remained high after GC treatment; Pancreatic diffuse enlargement; IgG4-SC with proximal bile duct involvement; Involvement of extrapancreatic organs;
- Indications for treatment, (1) symptomatic individuals may experience pancreatic involvement (such as obstructive jaundice, abdominal pain, lower back pain, etc.) and extrapancreatic organ involvement (such as jaundice caused by bile duct stenosis, etc.); (2) Asymptomatic individuals, who may develop subclinical AIP (persistent pancreatic mass, liver dysfunction with proximal IgG4 associated sclerosing cholangitis) with severe and irreversible damage to important organs;
- Able to persist and cooperate with research interventions, such as oral medication;
- If it is a woman in the reproductive period, contraception should be used for at least one month before screening, and a commitment should be made to use contraception throughout the entire study period and continue until the specified time after the end of the study
Exclusion Criteria:
- Pregnant/lactating women; Inability or refusal to sign informed consent form;
- History of mental illness;
- Allergy to research interventions;
- With malignant tumors;
- Active hepatitis/tuberculosis and other infectious diseases;
- With underlying diseases that are difficult to control, such as severe heart failure, respiratory failure, etc;
- Within 3 months, use of glucocorticoids or immunosuppressants due to other illnesses
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: Glucocorticoids group
Induction therapy: Prednisone 30mg/d, lasting for 4 weeks, then decreasing by 5mg/d every 2 weeks until maintained at 5mg/d. Peripheral blood samples will also be collected for exploratory mechanistic analyses. |
The study subjects were randomly divided into a GC monotherapy maintenance group and a GC combined with MMF maintenance group in a 1:1 ratio. The randomization sequence was generated online using a computer randomization scheme. Group A was the GC monotherapy maintenance group
Autres noms:
|
|
Expérimental: Glucocorticoids+MMF group
GC: Induction therapy: 30mg/d, lasting for 4 weeks, then decreasing by 5mg/d every 2 weeks until maintained at 5mg/d. At the initial stage of simultaneous treatment, 1.0g-1.5g MMF combined with GC treatment. Peripheral blood samples will also be collected for exploratory mechanistic analyses. |
The study subjects were randomly divided into a GC monotherapy maintenance group and a GC combined with MMF maintenance group in a 1:1 ratio. The randomization sequence was generated online using a computer randomization scheme. Group B was the GC+MMF maintenance group
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Disease remission rate within 3 years in high-risk type I AIP patients receiving glucocorticoid monotherapy versus glucocorticoid combined with MMF maintenance therapy
Délai: 3 years
|
Disease remission is defined as the proportion of patients achieving complete or partial resolution of clinical symptoms, normalization or significant improvement of imaging findings, and reduction of serum IgG4 levels. Remission rate will be compared between the glucocorticoid monotherapy group and the glucocorticoid plus MMF combination therapy group within 3 years of follow-up. |
3 years
|
|
Disease remission rate within 1 years in high-risk type I AIP patients receiving glucocorticoid monotherapy versus glucocorticoid combined with MMF maintenance therapy
Délai: 1 year
|
Disease remission is defined as the proportion of patients achieving complete or partial resolution of clinical symptoms, normalization or significant improvement of imaging findings, and reduction of serum IgG4 levels. Remission rate will be compared between the glucocorticoid monotherapy group and the glucocorticoid plus MMF combination therapy group within 1 years of follow-up. |
1 year
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Changes in endocrine function
Délai: 3 years
|
Endocrine function will be assessed by the following measures: (1) incidence of new-onset diabetes mellitus during the 3-year follow-up period; (2) change from baseline in HbA1c levels; (3) change from baseline in C-peptide levels; (4) change from baseline in insulin secretion capacity. |
3 years
|
|
Changes in external secretion pancreatic function
Délai: 3 years
|
Pancreatic exocrine function will be assessed by the following measures: (1) incidence of pancreatic exocrine insufficiency during the 3-year follow-up period; (2) change from baseline in serum vitamin levels (including vitamin A, D, E); (3) change from baseline in serum 25-OH-D3 levels. |
3 years
|
|
Incidence of malignant tumors
Délai: 3 years
|
Incidence of newly diagnosed malignant tumors, specifically gastrointestinal tumors (including esophageal, gastric, pancreatic, and colorectal tumors), detected by endoscopic examination during the 3-year follow-up period. All tumor diagnoses will be confirmed by histopathological evaluation. |
3 years
|
|
Adverse reactions
Délai: 3 years
|
Adverse reactions including the allergic reactions to drugs |
3 years
|
|
Treatment costs
Délai: 3 years
|
to assess the total treatment costs in 3 years |
3 years
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Duowu Zou, Doctor, Ruijin Hospital
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Processus pathologiques
- Maladie chronique
- Attributs de la maladie
- Maladies auto-immunes
- Maladies du système immunitaire
- Maladies du système digestif
- Maladies pancréatiques
- Pancréatite chronique
- Conditions pathologiques, signes et symptômes
- Pancréatite
- Pancréatite auto-immune
- Récurrence
- Effets physiologiques des drogues
- Hormones
- Hormones, substituts hormonaux et antagonistes hormonaux
- Actions pharmacologiques
- Actions et utilisations chimiques
- Composés polycycliques
- Prégnades
- Grossesse
- Stéroïdes
- Composés à anneau fusionné
- Grossissements
- Hormones cortex surrénaliques
- Prednisone
- Glucocorticoïdes
Autres numéros d'identification d'étude
- KY2024-107
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
No plan to share IPD
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .